Evidence map›Paper›PMID 41945920›Full record

ArticleJournal of medical Internet research2026

Feasibility and Acceptability of AI-Powered Tools for Early Autism Screening in Egypt: Semistructured Focus Group Study.

Pratheepan Yogarajah, Ammal M Metwally, Priyanka Chaurasia, Ghada A Elshaarawy, Shereen M El Khateeb, Engy A Ashaat, Amal Elsaeid, Nahed A Elghareeb, Amira S ElRifay

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pratheepan Yogarajah *School of Computing, Engineering & Intelligent Systems, Ulster University, Londonderry, Northern Ireland, United Kingdom.ORCID https://orcid.org/0000-0002-4586-7228
Ammal M Metwally *National Research Centre, Giza, Giza, Egypt.ORCID https://orcid.org/0000-0003-0575-5202
Priyanka ChaurasiaSchool of Computing, Engineering & Intelligent Systems, Ulster University, Londonderry, Northern Ireland, United Kingdom.ORCID https://orcid.org/0000-0003-4249-3678
Ghada A ElshaarawyNational Research Centre, Giza, Giza, Egypt.ORCID https://orcid.org/0000-0001-7165-0594
Shereen M El KhateebDepartment of psychology, American University in Cairo, Cairo, Egypt.ORCID https://orcid.org/0009-0007-5409-2499
Engy A AshaatNational Research Centre, Giza, Giza, Egypt.ORCID https://orcid.org/0000-0002-2116-1570
Amal ElsaeidNational Research Centre, Giza, Giza, Egypt.ORCID https://orcid.org/0000-0002-1569-7002
Nahed A ElghareebMinistry of Health and Population, Cairo, Egypt.ORCID https://orcid.org/0000-0002-5082-8792
Amira S ElRifayNational Research Centre, Giza, Giza, Egypt.ORCID https://orcid.org/0000-0002-6181-1072

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutism spectrum disorder (ASD) is often underdiagnosed in low- and middle-income countries due to limited specialist access, sociocultural stigma, and fragmented screening systems. Artificial intelligence (AI)-powered screening tools may improve early detection by enabling low-cost, accessible assessments. However, adoption depends on stakeholder trust, ethical safeguards, and alignment with local health system capacities.

objectiveThis study explored the feasibility, acceptability, and perceived ethical and practical enablers and barriers to implementing AI-powered tools for early ASD screening in Egypt, with attention to urban-rural disparities and integration into existing care pathways.

methodsWe used a qualitative design with semistructured focus group discussions with 49 participants (21 parents of children with ASD and 28 health care professionals) recruited from urban and rural governorates. Discussions were audio-recorded, transcribed verbatim, and analyzed using Braun and Clarke's reflexive thematic analysis, supported by NVivo software (Lumivero). Methodological integrity was ensured through reflexivity, triangulation, and peer debriefing. Thematic saturation was monitored across groups, and participant diversity was prioritized across contexts.

resultsFive themes emerged: (1) AI as a supportive tool rather than a replacement for clinicians, emphasizing scalability and assistance for nonspecialists; (2) the need for cultural and contextual adaptation to ensure local relevance; (3) privacy, trust, and transparency concerns, including data security, consent, and algorithmic opacity; (4) reducing diagnostic inequities by addressing urban-rural disparities and strengthening community-based deployment; and (5) the preference for hybrid AI-human models, with conditions for adoption including cultural sensitivity, human oversight, and digital literacy support. Counts (n/N) of parents and health care professionals contributing to each theme were used descriptively as indicators of pattern salience rather than as statistical estimates of prevalence. Participants expressed cautious optimism, with parents emphasizing accessibility and speed, while health care professionals highlighted concerns about reliability, cultural adaptation, and data governance.

conclusionsAI-powered ASD screening has potential to advance equitable early detection in underserved areas. Adoption requires transparent data governance, integration into hybrid human-AI models, culturally adaptive design, and targeted digital literacy initiatives. These findings provide an evidence-based roadmap for policymakers, technologists, and health system leaders to implement AI screening tools that are ethically sound, contextually relevant, and equity-focused.

Indexed as

Artificial IntelligenceAutism Spectrum DisorderMass ScreeningAdultChildEgyptFeasibility StudiesFemaleFocus GroupsHumansMaleAIartificial intelligenceASDautism spectrum disorderdeveloping countriesEgypthealth equitymobile applicationsqualitative researchscreening

Identifiers

PMID41945920
PMCPMC13148128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.